Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Primary Hypertension
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to determine the effects of lavender oil inhalation on anxiety, sleep quality, and blood pressure in patients with primary hypertension. The study is designed as a double-blind randomized controlled trial. The study population consists of patients presenting to the Cardiology Outpatient Clinic of Ardahan State Hospital. Participants are randomly assigned to an experimental group, which will receive a total of 12 lavender oil inhalations three times a week for one month, or to a control group, which will continue routine treatment and care. Data will be collected using the Hypertension Diagnostic Form, Beck Anxiety Inventory, and Pittsburgh Sleep Quality Index. Statistical analyses will be conducted to compare outcomes between the experimental and control groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Other: Lavender — Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.

Primary Outcomes

  • Anxiety (Baseline, Week 2, Week 4)
  • Blood Pressure (Baseline, Week 2, Week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-07
Completion: 2025-10-09
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ardahan University
Contact Information
Study Contact:
Derya ŞİMŞEKLİ, PhD
+905545965789
deryasimsekli@ardahan.edu.tr
Derya ŞİMŞEKLİ, PhD
+9005545965789
deryasimsekli@ardahan.edu.tr
Ardahan State Hospital
Ahmet Oğuz CESUR, Dr.
Ardahan State Hospital
Interventions
  • Other: Lavender — Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.
Study Locations (1 sites)
Ardahan State Hospital, Ardahan, Ardahan 75000 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Diagnosed with primary hypertension * Willing to participate in the study * No allergy to lavender * No olfactory impairments * No history of psychiatric disorders Exclusion Criteria: * Communication difficulties * Unwilling to participate * Using other herbal or aromatherapy treatments * History of sleep disorders affecting sleep quality (e.g., obstructive sleep apnea) * Secondary hypertension or other chronic diseases * Pregnant or breastfeeding * Use of tobacco products
Conditions Breast Cancer, Capsular Contracture Asso...
Phase NA
Enrollment 250
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the capacity of the NovaGray RILA Breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: NovaGray RILA Breast® test — The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.

Primary Outcomes

  • Ability of a radiosensitivity test to predict capsular contracture (12 months after the end of radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-11
Completion: 2031-12-10
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • Marian Gutowski (STUDY_CHAIR) - Institut du Cancer de Montpellier - Val d'Aurelle
Contact Information
Study Contact:
Aurore MOUSSION
04 67 61 31 02
DRCI-icm105@icm.unicancer.fr
Emmanuelle TEXIER
04 67 61 31 02
DRCI-icm105@icm.unicancer.fr
Laura VINCENT
lvincent@cgfl.fr
Centre Georges François Leclerc
Interventions
  • Device: NovaGray RILA Breast® test — The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
Study Locations (9 sites)
Centre Georges François Leclerc, Dijon, 21079 France
Centre Oscar Lambret, Lille, 59000 France
Centre Léon Bérard, Lyon, 69373 France
Institut Paoli Calmette, Marseille, 13009 France
Institut du Cancer de Montpellier, Montpellier, 34298 France
centre Antoine Lacassagne, Nice, 06189 France
Hôpital Tenon, Paris, 75970 France
Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805 France
Institut Claudius Regaud, Toulouse, 31059 France
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed * Indication of wall chest radiation after mastectomy * Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center) * Performance Status 0-1 * Consent signed before any study procedure * Patient geographically accessible for follow-up * Affiliated to the French national social security system Exclusion Criteria: * Breast reconstruction with flap * Inflammatory breast cancer (cT4d) * Skin or parietal breast cancer (cT4 a, b or c) * Metastatic patients * Patients with bilateral breast cancer * History of homolateral breast cancer treated with radiotherapy * History of contralateral breast cancer * Pregnant or breastfeeding women * Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent * Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy
Conditions Breast Cancer
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

ASTER is a multi-part study that aims to prospectively establish evidence for the implementation of aromatherapy as complementary therapy within cancer care in the Singapore context. ASTER 2 study evaluates how extracts from Asian aromatic plants with familiar aromas introduced as inhalation therapy can alleviate distress in breast cancer patients scheduled to undergo radiotherapy (RT).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: Carrier oil — Inhaler stick containing 2 drops of carrier oil.
  • Other: Asian plant extract blend — Inhaler stick containing 2 drops of Asian plant extract blend.

Primary Outcomes

  • The impact of Inhalation Aromatherapy Intervention on Distress. (Baseline (on CT Simulation Day), Before Intervention (on RT day), and After 20 minutes of Aromatherapy Intervention (on RT day).)
  • The impact of Inhalation Aromatherapy Intervention on Anxiety. (Baseline (on CT Simulation Day), After 20 minutes of Aromatherapy Intervention (on RT day).)
  • The impact of Inhalation Aromatherapy Intervention on Cortisol (stress hormones). (Before Intervention (on RT day), After 20 minutes of Aromatherapy Intervention (on RT day).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-22
Completion: 2027-06-01
Eligibility
Age: 21 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Centre, Singapore
Principal Investigators:
  • Dr. Fuh-Yong Wong, MBBS, FRCR (PRINCIPAL_INVESTIGATOR) - National Cancer Centre, Singapore
Contact Information
Study Contact:
Dr. Fuh-Yong Wong, MBBS, FRCR
+65 63061110
wong.fuh.yong@singhealth.com.sg
Dr. Fuh-Yong Wong, MBBS, FRCR
+65 63061110
wong.fuh.yong@singhealth.com.sg
National Cancer Centre Singapore
Interventions
  • Other: Carrier oil — Inhaler stick containing 2 drops of carrier oil.
  • Other: Asian plant extract blend — Inhaler stick containing 2 drops of Asian plant extract blend.
Study Locations (1 sites)
National Cancer Centre Singapore, Singapore, 168583 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Aged 21 years old and above 2. Confirmed diagnosis of breast cancer of any stage 3. Scheduled to undergo radiotherapy for the first time 4. Capable of providing informed consent Exclusion Criteria: 1. Physically or mentally incapable of providing verbal/written consent 2. Known or suspected hypersensitivity/allergy to essential oils or any components of the formulations 3. Airway hypersensitivity to fragrances, paint fumes or turpentine 4. Taking medications for anxiety (e.g. benzodiazepines) before radiotherapy 5. Pregnant, breastfeeding, or intending to conceive during study period
Conditions Metastatic Breast Cancer
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine Pill — Will be given once per day by mouth

Primary Outcomes

  • Objective response rate (RR) evaluation (Baseline up to 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-14
Completion: 2028-06
Eligibility
Age: 60 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Humaria Sarfraz, MD (PRINCIPAL_INVESTIGATOR) - The University of Alabama at Birmingham
Contact Information
Study Contact:
Margaret Thomas, MPH
205-895-1802
margaretathomas@uabmc.edu
Katia Khouri, MD
216-556-3035
katia.khoury@gunet.georgetown.edu
Humaria Sarfraz, MD
205-975-2891
humairasarfraz@uabmc.edu
University of Alabama at Birmingham
Interventions
  • Drug: Capecitabine Pill — Will be given once per day by mouth
Study Locations (1 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed breast cancer with HER2 negative status. A copy of the pathology report is required at the time of enrollment. 1. HER2 negativity will be determined by in situ hybridization (ISH) non- amplified and IHC 0 or 1+ or 2+. 2. Patients with HR (hormone receptor) positive and triple negative breast cancer (TNBC) will be eligible for enrollment. 2. Metastatic or locally advanced breast cancer, with at least one measurable lesion according to RECIST (v1.1). 3. ECOG performance status of 0-2. 4. Patients must have progressed on at least 1 prior line of therapy in the metastatic setting (hormonal therapy or chemotherapy) 5. Adequate organ function as evidenced by: 1. ANC \>1.5 x 10⁹/L (1500/µL) or \> 1.3 x 10⁹/L (1300/µL) for patients with history of benign ethnic neutropenia. 2. Platelet count ≥100,000/µL (without transfusion within 2 weeks prior to initiation of study treatment (Cycle 1, day 1)). 3. Hemoglobin ≥9.0 g/dl. Patients may be transfused or receive erythropoietic treatment to meet this criterion. 4. AST, ALT, and alkaline phosphatase ≤2.5 x upper limit of normal (ULN) with following exceptions: I. Patients with documented liver metastasis: AST and ALT ≤5 x ULN II. Patients with documented liver or bone metastasis: alkaline phosphatase ≤5 x ULN 5. Serum bilirubin ≤1.5 x ULN • Patients with known Gilbert disease who have serum bilirubin level ≤3 x ULN may be enrolled. 6. INR and aPTT ≤1.5 x ULN • This applies only to the patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. 7. Creatinine clearance \> 30 mL/min (measured using Cockcroft-Gault equation or estimated glomerular filtration rate from the Modification of Diet in Renal Disease Study) 6. Patients must be able to provide signed informed consent. 7. Female patients of any ethnic group. Female patients must be surgically sterile, postmenopausal (no menses for at least one year), or using medically approved method of contraception (excluding rhythm, withdraw or abstinence). Men must agree to use a medically approved method of contraception (excluding rhythm, withdraw or abstinence). 8. Patients ≥60 years old and/or frail patients at any age, defined by the investigator as an individual at greater risk of complications and poorer outcomes with systemic therapy, secondary to a lower physiologic reserve and higher comorbidities and functional deficits. 9. Complete initial work-up within 2 weeks prior to start of treatment (Cycle 1 Day 1). 10. Patients known to be HIV positive are eligible if they meet the inclusion criteria. Exclusion Criteria: 1. Any history of treatment with Capecitabine in metastatic setting. 2. Patients who only have non-measurable disease. 3. Patients with severe hepatic (bilirubin \> 3 times upper limit of normal) or renal failure (CrCl \< 30 calculated using Cockcroft-Gault formula). 4. Patients who are unable to swallow pills 5. Patients with HER2 positive breast cancer 6. Major surgical procedure within 3 weeks prior to study entry. 7. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>2 weeks prior to initiation of study treatment (Cycle 1, Day 1)
Conditions Early Breast Cancer, Radiation Associate...
Phase NA
Enrollment 1502
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The majority of early breast cancer patients are treated with adjuvant radiation therapy (RT) as part of their multimodal therapy. The aim of the RT is to lower the risk of local, regional and distant failure and improve survival. Modern RT is been provided with photon therapy. Now, more proton therapy facilities are opened, including in Denmark. Proton RT may have the potential to cause lower dose to heart and lung during breast RT. This trial will randomise patients between standard photon RT versus experimental proton RT. The primary endpoint is 10 year risk of heart disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Proton versus photon radiation therapy — The intervention is proton radiation therapy versus photon radiation therapy

Primary Outcomes

  • Radiation associated ischaemic and valvular heart disease (10 years after RT)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-06-01
Completion: 2037-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1502 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Danish Breast Cancer Cooperative Group
Principal Investigators:
  • Birgitte V Offersen, phd (PRINCIPAL_INVESTIGATOR) - Danish Breast cancer Cooperation Group (DBCG)
Contact Information
Study Contact:
Birgitte V Offersen, phd
+45 28838012
birgoffe@rm.dk
Morten Høyer, phd
+45 23282823
morthoey@rm.dk
Lars Stenbygaard, MD
Aalborg University Hospital
Interventions
  • Radiation: Proton versus photon radiation therapy — The intervention is proton radiation therapy versus photon radiation therapy
Study Locations (8 sites)
Aalborg University Hospital, Aalborg, Denmark
Aarhus University Hospital, Aarhus, Denmark
The Danish Breast Cancer Cooperative Group, Copenhagen, DK-2100 Ø Denmark
Rigshospitalet, Copenhagen, Denmark
Herlev Hospital, Herlev, Denmark
Naestved Hospital, Næstved, Denmark
Odense University Hospital, Odense, Denmark
Vejle Hospital, Vejle, Denmark
Eligibility Criteria
Inclusion Criteria: * Patient operated for early breast cancer with indication for radiation therapy, where standard planning shows a mean heart dose 4 Gy or more and/or a V20 lung of 37% or more. * Boost (breast, chest wall and nodal), breast reconstruction (any type, except implants with metal), connective tissue disease, post-operative surgical complications, any breast size and seromas are allowed * Patient with previous non-breast malignancy is accepted if the patient has been without disease minimum 5 years, and the treating oncologist estimates a low risk of recurrence. * Life expectancy minimum 10 years Exclusion Criteria: * previous breast cancer/ductal carcinoma in situ, * Previous RT to the chest region * Pregnant or lactating * Conditions indicating that the patient cannot go through the RT or follow up * Patients with Pacemaker or defibrillator are excluded until a guideline for handling them has been developed at the DCPT * Unknown non-tissue implants upstream of the target volume. NB. all such non-tissue, non-metal objects must be delivered to the DCPT for stopping power determination and evaluation at least a week prior to radiation start. * Metal implants in the radiation area, including metal in implants.
Conditions Breast Cancer
Phase EARLY_PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression. As part of the study design, a subset of patients will initially undergo dynamic PET/CT imaging to evaluate the safety profile and pharmacokinetic distribution of the radiotracer in vivo. Subsequently, static PET/CT imaging will be performed on additional patients to assess the diagnostic effectiveness of 68Ga-DOTA-dPNE. Imaging results will be correlated with relevant clinical indicators to evaluate the potential of this tracer in diagnosing breast cancer, guiding therapeutic decisions, and predicting responses to targeted therapies.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 68GA-DOTA-dPNE — Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection

Primary Outcomes

  • The evaluation of diagnostic performance of 68Ga-DOTA-dPNE PET in breast cancer (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-05-10
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Principal Investigators:
  • Xianzhong ZHANG (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Chenhao JIA
18548703382
jiachenhao24@163.com
Xianzhong ZHANG
18950190564
zhangxzh@pumch.cn
Chenhao JIA
18548703382
jiachenhao24@163.com
PUMCH
Interventions
  • Drug: 68GA-DOTA-dPNE — Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
Study Locations (1 sites)
PUMCH, Dongcheng, Beijing Municipality 100730 China
Eligibility Criteria
Inclusion Criteria: Female patients aged ≥18 years with an expected survival of at least 12 weeks No prior radiotherapy or chemotherapy; surgery or biopsy is feasible for pathological diagnosis At least one measurable target lesion as defined by RECIST v1.1 Able to provide written informed consent and comply with follow-up requirements Exclusion Criteria: Severe hepatic or renal dysfunction Pregnant, breastfeeding, planning to become pregnant, or planning to have children during the study period; women of childbearing potential must use effective contraception during the study Unable to lie flat for 30 minutes History of claustrophobia or other psychiatric disorders Any other condition deemed unsuitable for participation by the investigator Refusal to participate in the clinical study
Conditions Breast Cancer Survivorship, Breast Cance...
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The ultimate goal of this research and development is to develop personalized digital healthcare technologies and self-management strategies based on self-assessment results and evidence, for breast cancer survivors who require management and recovery from acute and chronic side effects related to various treatments (surgery, chemotherapy, radiation, hormone therapy, etc.). Additionally, the aim is to verify the clinical applicability and establish a service model to address the diverse unmet healthcare needs of breast cancer survivors.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Device: digital health (application and smartwatch) — The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.

Primary Outcomes

  • PROMIS29 (Baseline, Month 1, Month 3, Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-13
Completion: 2025-05-31
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Collaborators: Pusan National University Yangsan Hospital
Contact Information
Study Contact:
Sun Woo Kim, MS
+82-2-2008-4192
k.sunwoo0418@gmail.com
Sun Woo Kim
01055028826
k.sunwoo0418@gmail.com
Samsung Medical Center
Interventions
  • Device: digital health (application and smartwatch) — The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
Study Locations (1 sites)
Samsung Medical Center, Seoul, Republic of Korea 06351 South Korea
Eligibility Criteria
Inclusion Criteria: * Individuals who have undergone surgery for Stage 1-2 breast cancer * Individuals who have had a unilateral mastectomy * Aged 18 years or older and under 65 years * Possessing a smartphone with either an Android or iOS operating system * Individuals who voluntarily decide to participate after receiving detailed information about the study and provide written consent Exclusion Criteria: * Individuals who have undergone mastectomy only and are not receiving chemotherapy, radiation, or hormone therapy * Individuals with severe comorbidities (such as underlying diseases, neuromuscular disorders, cognitive or mental impairments, visual disabilities, etc.) that make it difficult to use the application or participate in the exercise intervention Discontinuation Criteria * Individuals who undergo delayed breast reconstruction surgery during the study period * Individuals who develop severe complications or experience cancer metastasis or recurrence in other organs during the study period, leading to a change in treatment * Occurrence of a major illness unrelated to study participation * Failure to comply with the instructions of the study physician * Situations where the participant voluntarily withdraws from the study or becomes unable to continue participating
Conditions Insomnia, Cognitive Impairment, Breast C...
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of the study is to investigate whether treating insomnia using app-based cognitive behavioral therapy for insomnia (CBT-I) can improve cognitive impairment in breast cancer survivors compared to an active control group (sleep hygiene education). The study will also explore if CBT-I is associated with changes in the brain and in inflammation. The investigators will recruit approximately 84 participants with insomnia and cognitive impairment who have completed breast cancer treatment within 1-5 years.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) — CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
  • Behavioral: Sleep hygiene education — \- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.

Primary Outcomes

  • Conners continuous performance test 3rd edition (Baseline (week 0), post-treatment (approximately week 9), 6-months follow-up (approximately week 33))
  • Insomnia Severity Index (ISI) (Baseline (week 0), post-treatment (approximately week 9), 6-months follow-up (approximately week 33))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-06
Completion: 2030-03-28
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aarhus University Hospital
Collaborators: University of Aarhus
Contact Information
Study Contact:
Ali Amidi
+4587165305
ali@psy.au.dk
Julie K. Thomadsen
+4587150192
jtho@psy.au.dk
Ali Amidi
+4587165305
ali@psy.au.dk
Aarhus University Hospital
Interventions
  • Behavioral: Cognitive Behavioral Therapy for Insomnia (CBT-I) — CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
  • Behavioral: Sleep hygiene education — \- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
Study Locations (1 sites)
Aarhus University Hospital, Aarhus N, Denmark
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Have completed primary breast cancer (BC) treatment within 1-5 years (endocrine therapies allowed) * Insomnia: a score of \>10 on the Insomnia Severity index (ISI) and/or meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for Insomnia Disorder * Cognitive impairment: a score of "quite a bit" or "very much" on at least 1 of the 2 items measuring concentration and memory on The European Organization for Research and Treatment of Cancer Core Quality of Life (EORCT-QLQ-C30) and/or \<54 on the Cancer Therapy-Cognitive (FACT-Cog) perceived cognitive impairment (PCI) subscale Exclusion Criteria: * Other sleep disorders than insomnia that may confound sleep and/or cognitive function * Use of drugs impacting that may confound sleep and/or cognitive function (endocrine therapies allowed) * Neurodegenerative and psychiatric disorders that may confound sleep and/or cognitive function * Shift work * Pregnancy or maternity leave * Recurrence of BC or new cancer * Insufficient Danish proficiency * Substance abuse that may confound sleep and/or cognitive function * Previous experience with CBT-I * Other cancer than breast cancer
Conditions Breast Cancer Detection, Breast Cancer E...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagnostic methods results in late diagnoses, leading to 1 in every 6 people dying from cancer today. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are found both inside cells and in bodily fluids such as blood and urine. Several studies have demonstrated their role in human diseases, especially cancer, where tumors release miRNAs into the bloodstream that can be used as biomarkers for early detection. The research and development team at Oncoliq SAS identified a panel of miRNAs associated with breast cancer, with a detection performance of 82% sensitivity and 83% specificity, validated in exploratory and preliminary confirmatory studies. These results led to the filing of a patent based on liquid biopsy technology. The objective of this protocol is to establish a panel of miRNAs for the early detection of breast cancer using samples from breast cancer patients and a cancer-free control group. Validation of the miRNAs will be carried out through RT-qPCR. This stage constitutes the analytical validation of the biomarkers, with the goal of developing an algorithm capable of classifying individuals with and without breast cancer. In future stages, a pilot clinical trial is planned to evaluate test implementation and clinical validation.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Peripheral blood draw — Collection of a blood sample for plasma isolation and miRNA analysis.

Primary Outcomes

  • Enrollment of 300 Participants (October to December 2025)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-17
Completion: 2026-02-28
Eligibility
Age: 40 Years – 70 Years
Sex: FEMALE
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oncoliq US Inc
Contact Information
Study Contact:
Adriana De Siervi, PhD in Molecular Biology
+54 11 3269 5832
adesiervi@oncoliq.bio
Camila Zaslavsky, Pharmacist
+54 11 2164 1626
camila@oncoliq.bio
Maria Abril Acosta, Oncologist
+54 11 6376-7387
acostamariaabril@gmail.com
DIM Centros de Salud
Interventions
  • Other: Peripheral blood draw — Collection of a blood sample for plasma isolation and miRNA analysis.
Study Locations (1 sites)
DIM Centros de Salud, Buenos Aires, Buenos Aires B1704 Argentina
Eligibility Criteria
Inclusion Criteria: Group 1 - Breast Cancer: Age between 40 and 70 years Diagnosis of breast cancer at any stage No prior surgical treatment No prior antineoplastic treatment Pathology report available at the time of enrollment Signed informed consent Group 2 - No Cancer (Control): Age between 50 and 70 years No diagnosis or personal history of any type of cancer Digital mammography and breast ultrasound showing no breast pathology (BI-RADS 1 or 2) Signed informed consent Exclusion Criteria: Refusal to sign the informed consent Communication issues that hinder understanding (hearing loss, blindness, intellectual disability, or dementia) Venipuncture for blood collection impracticable or posing a risk Personal history of previous cancer
Conditions Breast Cancer
Phase NA
Enrollment 850
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Italian multicentric non inferiority clinical study to verify whether the omission of axillary lymph node intervention in patients with SLN (Sentinel Lymph Nodes) ypN1mi after NAC (Neo Adiuvant Chemotherapy) does not lead to a significant deterioration in survival or in the risk of regional or distant recurrence, compared to patients with negative SLN (SLN ypN0) after NAC ,where the omission of axillary treatment is currently the standard treatment.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Procedure: Omission of Axillary dissection — In Group 1 and 2: Axillary dissection won't be performed

Primary Outcomes

  • Disease-free or death-free survival for any reason (DFS) (5 years of follow up after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-06-21
Completion: 2027-06-21
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituto Clinico Humanitas
Principal Investigators:
  • Corrado Tinterri, MD (PRINCIPAL_INVESTIGATOR) - Istituto Clinico Humanitas
Contact Information
Study Contact:
Corrado Tinterri, MD
+390282244012
corrado.tinterri@cancercenter.humanitas.it
Corrado Tinterri, MD
+390282244012
corrado.tinterri@cancercenter.humanitas.it
Istituto Clinico Humanitas
Interventions
  • Procedure: Omission of Axillary dissection — In Group 1 and 2: Axillary dissection won't be performed
Study Locations (1 sites)
Istituto Clinico Humanitas, Rozzano, MI 20089 Italy
Eligibility Criteria
Inclusion Criteria: 1. Age: 18 ≤75 years 2. Breast carcinoma with infiltrating histotype 3. Tumor size: cT1 - cT2 - cT3 4. Positive axillary lymph nodes (cN +) at the initial diagnosis by clinical, ultrasound and cyto-microhistology evaluation 5. Neoadjuvant chemotherapy performed 6. Negative axillary lymph nodes (cN-) from the NAC by clinical and ultrasound assessment 7. Absence of distant metastases (M0) 8. Negative medical history for previous infiltrating breast cancer Exclusion Criteria: 1. Current pregnancy or lactation status 2. Inflammatory breast cancer 3. In situ breast cancer 4. Synchronous contralateral breast cancer 5. Co-morbidity and/or medical disorder precluding any adjuvant therapy 6. Co-morbidity and/or medical/mental disorder making impossible making a regular follow-up 7. Other cancers in the previous 3 years (except forcarcinoma in situ of the uterine cervix, basalioma, squamous cell carcinoma or non-melanoma skin cancer)
Conditions Digestive Cancer, Gynecologic Cancer, Br...
Phase NA
Enrollment 4000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The BCB is a tool: * for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials; * to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations; * to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes. The creation of a broad clinical and biological prospective base dedicated to different types of cancer is essential for the development of such projects.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Biological: biological collection — * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.

Primary Outcomes

  • Proportion of patients who consent to participate in the study (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2017-07-27
Completion: 2037-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Principal Investigators:
  • jean pierre Bleuse (STUDY_CHAIR) - Institut régional du Cancer de Montpellier
Contact Information
Study Contact:
david azria
+33467613102
david.azria@icm.unicancer.fr
BLEUSE Jean-pierre, MHD
Institut regional du Cancer - Val d Aurelle
AZRIA David, PhD
Institut regional du Cancer - Val d Aurelle
Interventions
  • Biological: biological collection — * Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. * Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out.
Study Locations (1 sites)
Institut regional du Cancer - Val d Aurelle, Montpellier, 34298 France
Eligibility Criteria
Inclusion Criteria: * Age\> at 18 years old, * Patient with invasive or in situ tumor pathology (proven or suspected) any stage confounded, * Patient in ICM at diagnosis * a digestive cancer (esophagus, stomach, pancreas, colon, rectum, anal canal) or * gynecological cancer (ovary, endometrium, cervix) or * breast cancer or * sarcoma. * Naïve patient of any treatment for the present cancer, * Patient requiring treatment involving at least one (or more) tumor surgery (s) * Patient who has accepted supplementary blood samples, * Patient having given his informed, written and express consent. Exclusion Criteria: * Patient not affiliated to a social protection scheme, * Patient whose regular follow-up is a priori impossible for psychological, familial, social or geographical reasons, * Pregnant and / or nursing women, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation.
Conditions Early Stage Breast Carcinoma, Dyspnea
Phase NA
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Inspiratory muscle training — Training of respiratory muscles

Primary Outcomes

  • Maximum inspiratory pressure (Baseline to 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-16
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Principal Investigators:
  • Dharini M Bhammar, MBBS, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Dharini Bhammar
614-366-9467
dharini.bhammar@osumc.edu
Dharini M. Bhammar, MBBS, PhD
614-366-9467
Dharini.Bhammar@osumc.edu
Ohio State University Comprehensive Cancer Center
Interventions
  • Behavioral: Inspiratory muscle training — Training of respiratory muscles
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis * Able to exercise independently without needing support * Ability to read, speak, understand English Exclusion Criteria: * Metastatic breast cancer * Unwilling or unable to follow protocol requirements * Any significant health condition which in the investigator's opinion increases the risks of participation or makes the participant unsuitable for the study